Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage filings from Cardiff Oncology (CRDF) mix dense oncology science with complex regulatory detail. Whether you’re tracking financing rounds for onvansertib or reading the risk factors tied to PLK1 inhibition, finding the right data can be challenging. Investors regularly ask, “Where can I see Cardiff Oncology insider trading Form 4 transactions?” or “How does the latest Cardiff Oncology quarterly earnings report 10-Q filing affect cash runway?” We group those disclosures in one place and keep them updated the moment they hit EDGAR.
Stock Titan’s AI deciphers the text, turning hundreds of pages into concise insights. With real-time alerts, you’ll see Cardiff Oncology Form 4 insider transactions real-time, revenue trends from each Cardiff Oncology earnings report filing analysis, and the science discussed in every 8-K. Our platform offers:
- Cardiff Oncology SEC filings explained simply—plain-language notes beside each section.
- Cardiff Oncology annual report 10-K simplified with AI annotations linking clinical milestones to financial outcomes.
- Cardiff Oncology proxy statement executive compensation tables summarized so you can compare incentives to trial progress.
- Cardiff Oncology 8-K material events explained minutes after publication.
The result is a smoother research workflow. Need help understanding Cardiff Oncology SEC documents with AI? Use sentiment scores and key-phrase search to answer due-diligence questions fast. Prefer to monitor insider confidence? Our dashboard tracks every Cardiff Oncology executive stock transactions Form 4 alongside historical price moves. From liquidity analysis to pipeline catalysts, you’ll get the context you need without wading through jargon.
Cardiff Oncology director James O. Armitage received a new stock option grant on June 26, 2025. The derivative securities transaction details include:
- Granted 40,565 stock options to purchase common stock
- Exercise price set at $3.16 per share
- Options become exercisable on June 26, 2026
- Options expire on June 26, 2035
- Following this grant, Armitage now beneficially owns 187,539 derivative securities directly
This Form 4 filing represents a standard director compensation stock option grant, which vests one year from the grant date and has a 10-year exercise period. The transaction appears to be part of the company's regular director compensation program rather than an open market transaction.
Cardiff Oncology (Nasdaq:CRDF) filed a Form 8-K detailing the 26 June 2025 Annual Meeting vote results.
- All seven director nominees were elected with roughly 20.5-21.2 M votes in favor and no votes against.
- Shareholders ratified BDO USA, P.C. as the independent auditor for FY 2025 (36.3 M for, 1.2 M against, 1.1 M abstain).
- An amendment raising the 2021 Equity Incentive Plan’s share reserve to 12.15 M shares passed (16.9 M for, 5.0 M against).
- The advisory say-on-pay resolution was approved (18.9 M for, 2.6 M against).
No other material business or operational updates were disclosed.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
What is the primary focus of Cardiff Oncology Inc?
Which cancer indications are being explored by Cardiff Oncology?
How does PLK1 inhibition contribute to cancer therapy?
What distinguishes Cardiff Oncology's approach in the competitive oncology market?
Where does Cardiff Oncology operate geographically?
How is Cardiff Oncology enhancing its E-E-A-T signals?
What role does onvansertib play in the company's portfolio?
